Abstract
The modest preventive efficacy seen in the RV144 vaccine trial in Thailand prompted an investigation of the recombinant canarypox vector (ALVAC-HIV)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
